Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Biogen Inc.

    NASDAQ: BIIB · Real-Time Price · USD
    138.87
    2.96 (2.18%)
    At close: Aug 19, 2025, 3:59 PM
    139.49
    0.45%
    Pre-market: Aug 20, 2025, 08:31 AM EDT
    2.18%
    Bid 139.2
    Market Cap 20.36B
    Revenue (ttm) 10B
    Net Income (ttm) 1.53B
    EPS (ttm) 10.45
    PE Ratio (ttm) 13.29
    Forward PE 8.31
    Analyst Hold
    Ask 139.6
    Volume 1,104,990
    Avg. Volume (20D) 1,435,517.7
    Open 136.46
    Previous Close 135.91
    Day's Range 136.02 - 139.58
    52-Week Range 110.04 - 207.59
    Beta 0.13

    About BIIB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol BIIB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for BIIB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Biogen Inc. is scheduled to release its earnings on Oct 29, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 weeks ago
    +1.07%
    Biogen shares are trading higher after the company... Unlock content with Pro Subscription
    6 months ago
    -4.28%
    Biogen shares are trading lower after the company issued FY25 adjusted EPS guidance below estimates.
    news image

    1 week ago · businesswire.com

    Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

    BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...

    news image

    2 weeks ago · seekingalpha.com

    Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio

    Biogen beat Q2 2025 revenue and EPS estimates, but core MS and SPINRAZA franchises continue to erode, offset only partially by new products. Launches like ZURZUVAE and LEQEMBI show promise, yet their ...

    2 weeks ago · youtube.com

    Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

    Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

    2 weeks ago · youtube.com

    President Trump demands drugmakers slash prices within 60 days

    CNBC's Joe Kernen reports on the latest news.

    news image

    2 weeks ago · seekingalpha.com

    Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

    Biogen Inc. (NASDAQ:BIIB ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Alisha A. Alaimo - President & Head of North America Christopher A.

    news image

    2 weeks ago · zacks.com

    Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

    BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

    news image

    2 weeks ago · zacks.com

    Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

    Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street es...

    news image

    2 weeks ago · zacks.com

    Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates

    Biogen Inc. (BIIB) came out with quarterly earnings of $5.47 per share, beating the Zacks Consensus Estimate of $3.93 per share. This compares to earnings of $5.28 per share a year ago.

    news image

    2 weeks ago · reuters.com

    Biogen raises annual profit forecast on strong demand for rare disease drugs

    Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs.

    news image

    2 weeks ago · zacks.com

    Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

    Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quar...

    Add to Watchlist